When selecting genetically modified or syngeneic transplant mouse models for preclinical tests regulating or targeting fibrillar collagens, models with a range of cancer-cell-derived COL1A1 expression need to be assessed to be representative of the wide variations seen in human PDAC. Here, COL1A1 is linked to cancer.